Zogenix is a pharmaceutical company based in Emeryville and San Diego with an FDA‑approved needle‑free delivery product, SUMAVEL™ DosePro™ (sumatriptan injection). The company is preparing for the commercial launch of SUMAVEL DosePro. It is also conducting a Phase 3 clinical development program of ZX002, an oral controlled‑release formulation of hydrocodone without acetaminophen for chronic pain. The recent financings are intended to support the SUMAVEL commercial launch and the ongoing Phase 3 program for ZX002. Proceeds will also be used to fully repay the outstanding balance of an existing term loan. Zogenix plans to license the patented DosePro needle‑free drug delivery system to other companies. Zogenix is an Emeryville and San Diego, CA-based pharmaceutical company focused on commercializing its SUMAVEL DosePro needle-free delivery system, the company’s first product. The company closed an increased Series B preferred stock financing to fund its near-term commercialization plans. The Series B was increased from $51M to $71M with a $35M second tranche recently closed. Existing investors including Clarus Ventures, Domain Associates, Scale Venture Partners, Thomas, McNerney & Partners and Abingworth Management participated, alongside new investor Oxford Finance Corporation and an additional $20M from Chicago Growth Partners. Chicago Growth Partners will take a board seat and be represented by Dr. Arda Minocherhomjee. The funds will be used to support the planned January 2010 launch of SUMAVEL DosePro. Zogenix focuses on developing and commercializing medicines to treat neuroscience disorders and pain. The company’s first product, SUMAVEL DosePro (a needle-free sumatriptan injection), recently received FDA approval. The $51M Series B preferred stock financing will fund the product's launch and commercial build-out. Zogenix plans to build a commercial organization of over 105 people to support the launch. The company has offices in Emeryville and San Diego, California. The financing comprises a first tranche and a callable remainder as detailed in the deal. Zogenix is a San Diego-based specialty pharmaceutical developer working on treatments for central nervous system (CNS) disorders and pain. It is developing two products, with its first product targeted at treating acute migraine. The company said it has raised an $18M secured loan facility to support preparation for that product's launch. The debt financing was provided by Oxford Finance Corporation and CIT Healthcare LLC. Zogenix has previously raised equity capital from investors including Abingworth Management, Clarus Ventures, Domain Associates, Life Science Angels, Scale Venture Partners, and Thomas, McNerney & Partners. The new funding is intended to help advance launch preparations for its lead program. Zogenix is a San Diego-based company that acquired a subcutaneous delivery platform to pursue migraine treatment development. The firm purchased Aradigm Corporation's Intraject subcutaneous delivery technology. Zogenix plans to develop and commercialize the acquired product. The company raised $60M in a Series A financing to fund the acquisition and subsequent development. Investors in the round include Clarus Ventures and Domain Associates, with participation from BA Venture Partners, Thomas, McNerney & Partners and Life Science Angels. No operating metrics or prior funding details are provided in the article.

Total raised

$214M

Funding rounds

6

Latest round

Debt Financing

Latest activity

Jul 2010